Skip to main content
SpringerLink
Log in

Recombinant factor VIIa (rFVIIa): its potential role as a hemostatic agent

  • Invited Review
  • Published:
Neuroradiology Aims and scope Submit manuscript

Abstract

Recombinant activated coagulation factor VII (rFVIIa) was developed for the treatment of patients with hemophilia who have developed inhibitors against the factor they are missing. Hemophilia is a serious bleeding disorder and patients with hemophilia develop repeated spontaneous CNS, joint and muscle bleeding. Any trauma, even mild events, may cause life-threatening bleeding, and without treatment, these patients have a life expectancy of about 16 years. Thus, hemophilia can be regarded as a model of severe bleeding, and an agent capable of inducing hemostasis in severe hemophilia independent of the hemophilia proteins (FVIII or FIX) may also be effective in patients without hemophilia who experience serious bleeds. The availability of rFVIIa stimulated research on the role of FVII and tissue factor (TF) in the hemostatic process. As a result, a picture partly different from the one suggested by previous models [1, 2] has emerged. These previous models basically neglected the role of cells and cell membranes. The importance of platelets and platelet membrane phospholipids in hemostasis has been demonstrated, and the new concept of the hemostatic process, focusing on cell surfaces, has been outlined.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Davie EW, Ratnoff O (1964) Waterfall sequence for intrinsic blood clotting. Science 145:1310–1312

    Article  PubMed  CAS  Google Scholar 

  2. MacFarlane RG (1964) An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature 202:498–499

    Article  PubMed  CAS  Google Scholar 

  3. Rapaport SI, Rao LV (1992) Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler Thromb 12:1111–1121

    PubMed  CAS  Google Scholar 

  4. Wildgoose P, Nemerson Y, Hansen LL, Nielsen EE, Glazer S, Hedner U (1992) Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood 80:25–28

    PubMed  CAS  Google Scholar 

  5. Hedner U, Erhardtsen E (2003) Potential role of recombinant factor VIIa as a hemostatic agent. Clin Adv Hematol Oncol 1:112–119

    PubMed  Google Scholar 

  6. Chen VM, Ahamed J, Versteeg HH, Berndt MC, Ruf W, Hogg PJ (2006) Evidence for activation of tissue factor by an allosteric disulfide bond. Biochemistry 45:12020–12028

    Article  PubMed  CAS  Google Scholar 

  7. Pendurthi UR, Ghosh S, Mandal S, Rao LVM (2006) Tissue factor activation: is disulfide switching a general regulatory mechanism? Blood (ASH Annual Meeting Abstracts) 108: Abstract 1747

  8. Mandal SK, Pendurthi UR, Rao LVM (2007) Tissue factor trafficking in fibroblasts: involvement of protease activated receptor-mediated cell signaling. Blood. DOI 10.1182/blood-2006-10-050476

  9. Konkle B, Friedrich U, Abrams Z (2006) Secondary prophylactic treatment with rFVIIa in patients with haemophilia A or B and inhibitors with high requirements for on-demand treatment. Poster presentation at the World Fed Haemophilia, Vancouver, Canada, May 2006. Haemophilia 12: Abstract 14 PO 363

    Google Scholar 

  10. Hedner U (2006) Potential role of recombinant factor FVIIa in prophylaxis in severe hemophilia patients with inhibitors. J Thromb Haemost 4:2498–2500

    Article  PubMed  CAS  Google Scholar 

  11. Bevers EM, Comfurius P, Zwaal RF (1991) Platelet procoagulant activity: physiological significance and mechanisms of exposure. Blood Rev 5:146–154

    Article  PubMed  CAS  Google Scholar 

  12. Monroe DM, Roberts HR, Hoffman M (1994) Platelet procoagulant complex assembly in a tissue factor-initiated system. Br J Haematol 88:364–371

    PubMed  CAS  Google Scholar 

  13. Monroe DM, Hoffman M, Olivier JA, Roberts HR (1997) Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 99:642–647

    Article  Google Scholar 

  14. Walsh PN (2004) Platelet coagulation-protein interactions. Semin Thromb Hemost 30:461–471

    Article  PubMed  CAS  Google Scholar 

  15. Monroe DM, Hoffman M, Roberts HR (2002) Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 22:1381–1389

    Article  PubMed  CAS  Google Scholar 

  16. Hedner U (2006) Mechanism of action, development and clinical experience of recombinant FVIIa. J Biotechnol 124:747–757

    Article  PubMed  CAS  Google Scholar 

  17. He S, Jacobsson Ekman G, Hedner U (2005) The effect of platelets on fibrin gel structure formed in the presence of recombinant factor VIIa in hemophilia plasma and in plasma from a patient with Glanzmann thrombasthenia. J Thromb Haemost 3:272–279

    Article  PubMed  CAS  Google Scholar 

  18. Galán AM, Tonda R, Pino M, Reverter JC, Ordinas A, Escolar G (2003) Increased local procoagulant action: a mechanism contributing to the favorable hemostatic effect of recombinant FVIIa in PLT disorders. Transfusion 43:885–891

    Article  PubMed  Google Scholar 

  19. Kenet G, Walden R, Eldad A, Martinowitz U (1999) Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 354:1879

    Article  PubMed  CAS  Google Scholar 

  20. Martinowitz U, Kenet G, Lubetski A, Luboshitz J, Segal E (2002) Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma. Can J Anaesth 49:S15–S20

    PubMed  Google Scholar 

  21. Martinowitz U, Michaelson M; The Israeli Multidisciplinary rFVIIa Task Force (2005) Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost 3:640–648

    Article  PubMed  CAS  Google Scholar 

  22. Segal S, Shemesh IY, Blumental R, Yoffe B, Laufer N, Mankuta D, Mazor M, Zohar S, Schiff E, Martinovitz U (2004) The use of recombinant factor VIIa in severe postpartum hemorrhage. Acta Obstet Gynecol Scand 83:771–772

    Article  PubMed  Google Scholar 

  23. Grounds M (1995) Recombinant factor VIIa (rfVIIa) and its use in severe bleeding in surgery and trauma: a review. Blood Rev 17:S11–S21

    Article  Google Scholar 

  24. Eikelboom JW, Bird R, Blythe D, Coyle L, Gan E, Harvey M, Isbister J, Leahy M, McIlroy D, Rahimpanah F, Ramanthan S, Strasser S, Ward C, Watts A, Towler S, Yi Q (2003) Recombinant activated factor VII for the treatment of life-threatening haemorrhage. Blood Coagul Fibrinolysis 14:713–717

    Article  PubMed  CAS  Google Scholar 

  25. Ahonen J, Jokela R (2005) Recombinant factor VIIa for life-threatening post-partum haemorrhage. Br J Anaesth 94:592–595

    Article  PubMed  CAS  Google Scholar 

  26. Boffard KD, Riou B, Warren B, Choong PI, Rizoli S, Rossaint R, Axelsen M, Kluger Y; NovoSeven Trauma Study Group (2005) Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 59:8–18

    Article  PubMed  CAS  Google Scholar 

  27. Friederich PW, Henny CP, Messelink EJ, Geerdink MG, Keller T, Kurth KH, Büller HR, Levi M (2003) Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 361:201–205

    Article  PubMed  CAS  Google Scholar 

  28. Astrup T (1991) Fibrinolysis: past and present, a reflection of fifty years. Semin Thromb Hemost 17:161–174

    PubMed  CAS  Google Scholar 

  29. Andersson L (1964) Antifibrinolytic treatment with epsilon-aminocaproic acid in connection with prostatectomy. Acta Chir Scand 127:552–564

    PubMed  CAS  Google Scholar 

  30. Andersson L (1974) Local fibrinolysis. In: Nilsson IM (ed) Haemorrhagic and thrombotic diseases. John Wiley & Sons, London, pp 155–182

    Google Scholar 

  31. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T; Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators (2005) Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 352:777–785

    Article  PubMed  CAS  Google Scholar 

  32. Counsell C, Boonyakarnkul S, Dennis M, et al (1955) Primary intracerebral haemorrhage in the Oxfordshire Community Stroke Project. 2. Prognosis. Cerebrovasc Dis 5:26–34

    Article  Google Scholar 

  33. Steiner T, Kaste M, Forsting M, Mendelow D, Kwiecinski H, Szikora I, Juvela S, Marchel A, Chapot R, Cognard C, Unterberg A, Hacke W (2006) Recommendations for the management of intracranial haemorrhage - Part 1: Spontaneous Intracerebral Haemorrhage The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Cerebrovasc Dis 22:294–316

    PubMed  Google Scholar 

  34. Mendelow AD, Gregson BA, Fernandes HM, Murray GD, Teasdale GM, Hope DT, Karimi A, Shaw MD, Barer DH; STICH investigators (2005) Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 365:387–397

    PubMed  Google Scholar 

  35. Lyden PD, Shuaib A, Lees KR, et al (2007) Final results of CHANT: a study of the safety and tolerability of NXY-059 in intracerebral hemorrhage (abstract). Stroke 38:475

    Google Scholar 

  36. Brott T, Broderick J, Kothari R, et al (1997) Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 28:1–5

    PubMed  CAS  Google Scholar 

  37. Davis SM, Broderick J, Hennerici M, Brun NC, Diringer MN, Mayer SA, Begtrup K, Steiner T; Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators (2006) Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology 66(8):1175–1181

    Article  PubMed  CAS  Google Scholar 

  38. Broderick JP, Diringer MN, Hill MD, Brun NC, Mayer SA, Steiner T, Skolnick BE, Davis SM (2007) Determinants of intracerebral hemorrhage growth: an exploratory analysis. Stroke 38:1072–1075

    Article  PubMed  CAS  Google Scholar 

  39. Steiner T, Diringer MN, Schneider D, Mayer SA, Begtrup K, Broderick J, Skolnick B, Davis SM (2006) Dynamics of intraventricular hemorrhage in patients with spontaneous intracerebral hemorrhage: risk factors, clinical impact, and effect of hemostatic therapy, with recombinant activated factor VII. Neurosurgery 59(4):767–773

    Article  PubMed  Google Scholar 

  40. Rice KM, Savidge GF (1996) Recombinant factor VIIa (r-FVIIa) in haemophilia management. Transfus Sci 17(3):339–340

    Article  PubMed  CAS  Google Scholar 

  41. Arkin S, Cooper HA, Hutter JJ, Miller S, Schmidt ML, Seibel NL, Shapiro A, Warrier I (1998) Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B inhibitors. Results of the NovoSeven emergency-use program. Haemostasis 28:93–98

    Article  PubMed  CAS  Google Scholar 

  42. Mayer SA, Brun N, Broderick J, et al (2005) Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. Stroke 36:74–79

    Article  PubMed  CAS  Google Scholar 

  43. Mayer SA, Brun NC, Broderick J, Davis SM, Diringer MN, Skolnick BE, Steiner T; United States NovoSeven ICH Trial Investigators (2006) Recombinant activated factor VII for acute intracerebral hemorrhage. US phase IIa trial. Neurocrit Care 4:206–214

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest statement

We are both employed by Novo Nordisk A/S, the manufacturer of rFVIIa (NovoSeven).

Author information

Authors and Affiliations

  1. University of Lund, Lund, Sweden

    Ulla Hedner

  2. Research & Development, Novo Nordisk A/S, Novo Nordisk Park, DK 2760, Maaloev, Denmark

    Ulla Hedner & Nikolai C. Brun

Authors
  1. Ulla Hedner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nikolai C. Brun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulla Hedner.

Additional information

This paper is one of a series of invited reviews.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hedner, U., Brun, N.C. Recombinant factor VIIa (rFVIIa): its potential role as a hemostatic agent. Neuroradiology 49, 789–793 (2007). https://doi.org/10.1007/s00234-007-0240-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00234-007-0240-2

Keywords

Search

Navigation